DR. ALBERT JOSEPH CALLAHAN III M.D.
Prescription History 1295722239
Pediatrics in West Springfield, MA

NPI Status: Active since October 04, 2005

Contact Information

373 PARK ST
WEST SPRINGFIELD, MA
ZIP 01089
Phone: (413) 734-1001
Fax: (413) 736-4875

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ALBERT JOSEPH CALLAHAN III M.D., an active Pediatrics specialist practicing in West Springfield, MA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 13 documented patient claims. Among these therapy options, the most frequently utilized medication is Roflumilast, which accounts for 13 claims alone.

Medication Index

No matching medications currently found on file.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 340
MA State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills18.8
Peer Average Days Supply553
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,017.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$155.22

State Avg Cost Per Claim

$332.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ALBERT JOSEPH CALLAHAN III M.D. provides transparency into local medical care patterns within West Springfield, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatrics** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.